Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Hepatitis B Virus (HBV) Market Grown from 2024 to 2025?
The market size for Hepatitis B Virus (HBV) has witnessed robust growth in the past few years. It is projected to expand from $6.71 billion in 2024 to $7.37 billion in 2025, registering a compound annual growth rate (CAGR) of 9.9%. Factors such as the increasing incidence of Hepatitis B Virus (HBV), burgeoning demand for HBV diagnostics, widening reach of HBV vaccines, and growing awareness about Hepatitis B Virus (HBV) have considerably contributed to the growth during the historic period.
What Growth Rate Is Anticipated for the Hepatitis B Virus (HBV) Market in the Coming Years?
Anticipated to exhibit robust growth in the forthcoming years, the market size of hepatitis B virus (HBV) is forecasted to escalate to $10.72 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%. Factors propelling growth during this forecast period include the emergence of personalized medicine, increased backing from patient advocacy groups, expansion of vaccination programs, and a surge in healthcare expenditure. Major trends forecast for this period encompass the creation of new drugs, advancements in diagnostic technologies, collaborations between public and private sectors, and introduction of innovative biological therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12867&type=smp
Who Are the Leading Companies in the Hepatitis B Virus (HBV) Market?
Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.
What Are the Key Drivers of the Hepatitis B Virus (HBV) Market?
The upswing in hepatitis B infection prevalence is anticipated to power the future growth of the hepatitis B virus market. The hepatitis B virus (HBV) causes a liver infection known as hepatitis B, which can be avoided through vaccination. The growth in the rates of hepatitis B infection could potentially stimulate demand for diagnostic procedures and treatment modalities. As per the information released by the World Health Organization, a Switzerland-based intergovernmental agency, in April 2024, 254 million individuals were impacted by chronic hepatitis B in 2022, with an annual emergence of 1.2 million fresh cases. Thus, the increased prevalence of hepatitis B infection is set to fuel the hepatitis B virus market. The hepatitis B virus market’s progression is predicted to be quickened by the enhanced incidences of liver damage or cirrhosis. Cirrhosis is a critical type of liver condition where scar tissue permanently takes up the place of healthy liver tissue. The hepatitis B virus affects the kidney function of patients while easing the symptoms and negative impact of the disease. For example, as per the data from the Office for Health Improvement and Disparities, a health and social care department based in the UK, in July 2023, England saw 82,290 hospital admissions due to liver disease in the financial year ending in 2022, a rate of 150.6 per 100,000 individuals. This is an increase from the 67,458 admissions recorded in the preceding financial year that ended in 2021. The increasing admission rate highlights a growing worry about liver health in the population. Therefore, the heightened occurrences of patients with liver damage or cirrhosis are propelling the growth of the hepatitis B virus market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12867&type=smp
What Are the Key Market Segments in the Hepatitis B Virus (HBV) Industry?
The hepatitis B virus (HBV) market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Treatment: Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery
3) By Age Group: Pediatrics, Adults, Seniors
4) By End User: Medical Providers, Patients, Healthcare Payers
Subsegments:
1) By Acute HBV: Asymptomatic Acute HBV, Symptomatic Acute HBV, Severe Acute HBV
2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive), Chronic Hepatitis B (HBeAg Negative), Chronic Hepatitis B With Compensated Liver Disease, Chronic Hepatitis B With Decompensated Liver Disease, Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)
What Are the Latest Trends in the Hepatitis B Virus (HBV) Market?
Major firms engaged in the Hepatitis B Virus (HBV) market are prioritizing the creation of superior diagnostic and treatment methodologies, such as the highly sensitive chemiluminescent microparticle immunoassay (CMIA), in order to establish a competitive market position. For instance, the American healthcare company, Abbott Laboratories, introduced the HBsAg Next Qualitative Solution Test in May 2022. This test facilitates earlier detection of Hepatitis B virus (HBV) in human serum and plasma samples, thereby enhancing patient prognosis and ensuring the safety of blood supplies. This highly sensitive CMIA technology enables early and more precise detection of HBV in human serum and plasma (blood) samples, as well as large-scale population screening.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
What Are the Key Regional Markets in the Hepatitis B Virus (HBV) Industry?
North America was the largest region in the hepatitis B Virus (HBV) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12867
This Report Delivers Insight On:
1. How big is the hepatitis b virus (hbv) market, and how is it changing globally?
2. Who are the major companies in the hepatitis b virus (hbv) market, and how are they performing?
3. What are the key opportunities and risks in the hepatitis b virus (hbv) market right now?
4. Which products or customer segments are growing the most in the hepatitis b virus (hbv) market?
5. What factors are helping or slowing down the growth of the hepatitis b virus (hbv) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
